Opendata, web and dolomites

MagnoBeads

Removing endotoxins during sepsis: a blood purification platform using magnetic nanoparticles

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MagnoBeads project word cloud

Explore the words cloud of the MagnoBeads project. It provides you a very rough idea of what is the project "MagnoBeads" about.

halted    19    uniquely    2017    founded    exists    selectively    relieving    stabilizing    billion    death    rate    treat    sized    authorization    commercialization    huge    trials    responsible    opportunity    swiss    solid    engineering    uuml    cure    spin    capitalize    2026    combined    nanoparticle    delivering    treatments    commercial    filtered    platform    regulatory    human    care    financially    30    ongoing    composition    clinical    strategies    capture    removing    evaluation    models    units    dialysis    successfully    eth    molecules    academic    device    move    endotoxins    intensive    purification    filter    entails    animal    feasibility    ready    zurich    usability    million    position    put    employs    patient    company       curative    sepsis    subsequently    proprietary    wyss    smei    freedom    treatment    receive    people    market    nanoparticles    ip    blood    prototype    designed    commercialize    magnetic    operate    tested    off    hemotune    gebert    mortality    symptoms    strategy    financial    excellent    septic    foundation    upscaling    small    removes   

Project "MagnoBeads" data sheet

The following table provides information about the project.

Coordinator
HEMOTUNE AG 

Organization address
address: C/O ETH ZURICH WEINBERGSTRASSE 35 WEH F14
city: ZURICH
postcode: 8092
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://www.hemotune.ch
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HEMOTUNE AG CH (ZURICH) coordinator 50˙000.00

Map

 Project objective

Hemotune is a Swiss academic spin-off company founded in 2017 to commercialize proprietary blood purification technology using uniquely designed magnetic nanoparticles, developed at ETH Zürich. Hemotune is financially supported by Wyss Zurich and the Gebert Rüf foundation to develop a product to treat sepsis. Sepsis affects 19 million people each year, and with a mortality rate of 30% it is the most common cause of death in intensive care units. Currently, no cure for sepsis exists, and treatment focuses on relieving symptoms. Therefore, a huge market opportunity exists for curative sepsis treatments, which is estimated to reach €4.3 billion by 2026.

Using its proprietary blood purification technology, hemotune aims to capitalize on this market opportunity by developing a dialysis-like device that removes endotoxins (molecules responsible for sepsis) from the blood. This device employs magnetic nanoparticles to selectively capture endotoxins, which are subsequently filtered out of the blood by a magnetic filter. By removing these endotoxins, the septic response is halted, stabilizing the patient. This technology was successfully tested in small-scale animal models, and now R&D activities will focus on developing a human-sized prototype product, ready for clinical evaluation.

Financial support from the SMEi phase 1 will be used to assess the technical and commercial feasibility of the nanoparticle-based blood purification platform as a treatment strategy for sepsis. Technical feasibility includes usability engineering, and feasibility studies into the upscaling, and into regulatory feasibility to receive market authorization. Commercial feasibility entails a freedom to operate analysis, and composition of solid IP and commercialization strategies. This SMEi phase 1 feasibility study, combined with the ongoing R&D delivering the prototype product, put hemotune in an excellent position to rapidly move forward towards clinical trials.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAGNOBEADS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAGNOBEADS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More